Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

**Topic 11: The Pharmaceutical Industry Perspective**
The Pharmaceutical Industry perspective

Shakira Ramlakhan (LLB) (LLM)
Health Projects and Information Manager (IMSA)
in collaboration with
The Pharmaceutical Industry Association of SA (PIASA)

Regional Seminar for Certain African Countries on the Implementation and Use Of Several Patent-related Flexibilities
Mapping of pharmaceutical manufacturing capacity in Africa

- Total of 129 companies identified
- Most companies locate to Egypt, SA, Nigeria, Morocco and Algeria
- Estimated average sales for identified companies of ~USD 90 million/year
4: Reducing child mortality: Reduce by two-thirds the under-five mortality rate, (4.3%)

5: Improving maternal health: reduce by \(\frac{3}{4}\) maternal mortality ratio, (5.4%).

6: Combating HIV/AIDS, malaria and other diseases. Halt and begin to reverse the spread of the diseases by 2015.
NEW MEDICINES HAVE PROLONGED LIFE

Drop in Death Rate for Diseases Treated with Pharmaceuticals, 1965–1995

<table>
<thead>
<tr>
<th>Disease</th>
<th>Percent Drop in Death Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Infancy Diseases</td>
<td>80%</td>
</tr>
<tr>
<td>Rheumatic Fever and Rheumatic</td>
<td>75%</td>
</tr>
<tr>
<td>Heart Disease</td>
<td></td>
</tr>
<tr>
<td>Atherosclerosis</td>
<td>68%</td>
</tr>
<tr>
<td>Hypertensive Heart Disease</td>
<td>67%</td>
</tr>
<tr>
<td>Ulcer of Stomach and Duodenum</td>
<td>61%</td>
</tr>
<tr>
<td>Ischemic Heart Disease</td>
<td>41%</td>
</tr>
<tr>
<td>Emphysema</td>
<td>31%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>22%</td>
</tr>
</tbody>
</table>

Source: PhRMA, Based on Boston Consulting Group, 1993; and US National Center for Health Statistics, 1998
## NEW SCIENCE IS CHANGING HEALTHCARE

<table>
<thead>
<tr>
<th>Area</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structural Biology</td>
<td>Rational design of new medicines</td>
</tr>
<tr>
<td>Genetics, genomics and proteomics</td>
<td>Better targeting of medicines</td>
</tr>
<tr>
<td>Metabonomics</td>
<td>Better diagnosis and monitoring</td>
</tr>
<tr>
<td>Vaccines and immunomodulation</td>
<td>Prevention and monitoring of infectious diseases</td>
</tr>
<tr>
<td>Point of care diagnostics</td>
<td>Faster diagnosis and enhanced involvement of the patient</td>
</tr>
<tr>
<td>Bionics</td>
<td>Organ replacement and enhancement</td>
</tr>
<tr>
<td>Cell and tissue engineering</td>
<td>Regenerative medicine</td>
</tr>
<tr>
<td>Imaging</td>
<td>Better diagnosis and precision treatment</td>
</tr>
<tr>
<td>Micro-electronic devices</td>
<td>Sensing and monitoring; increased independence for individuals</td>
</tr>
<tr>
<td>Minimally invasive and robotic surgery</td>
<td>Enhanced precision and reduction in unwanted drama</td>
</tr>
</tbody>
</table>

Source: Sir Richard Sykes, Imperial College London
HIV Mortality Declined Dramatically After Introduction of First “Expensive” Antiretrovirals...

First new drugs introduced, 1995
Highly Active Antiretroviral Therapy (HAART) introduced, 1996-97

...While Monthly Costs for AIDS Patients Decreased by 16% After HAART Introduced

Where were AIDS Drugs Discovered?
- NIH: 9%
- Industry: 91%

Large numbers of drugs to treat AIDS

PRESCRIPTION DRUGS SAVE LIVES & MONEY

Source: Costs - Bozette et al., New England Journal of Medicine Vol. 344, No. 11, March 15, 2001; Mortality - Centers for Disease Control; data on drug development from PhRMA and the NIH Office of Technology transfer
INNOVATIVE MEDICINES ADD VALUE

• Patients care about:
  • Increased longevity
  • Increased quality of life
  • Prevention of disability
  • Maintaining autonomy and independence

• Employers care about:
  • Potential for direct offset to other health care costs
  • Increased workplace productivity
  • Decrease in absenteeism

• Doctors care about:
  • Ability to replace costly surgery

Innovative medicines have been shown to add value across the spectrum – there are many examples
THE ARGUMENT FOR ACCESS TO INNOVATIVE PHARMACEUTICALS

Drugs and vaccines – eliminated/control many diseases and conditions that once had high mortality rates (e.g., influenza, polio, pneumonia, and diphtheria).

Dramatically reduce mortality rates for other diseases and conditions (e.g., AIDS, asthma, heart attacks, strokes, and ulcers).

Trend will continue with new medicines significantly reducing mortality from disease.

Newer drugs have improved side effect profiles with better compliance.
PATIENT PERSPECTIVES
The Patient Perspective

3/5 survived - options
Bone marrow transplant or Interferon

New pill targets CML at cellular level – remission possible with fewer side effects

Less side effects and greater response rate

Control with unpleasant side effects

Schizophrenia

Between the 1950s and the 1980s, the antipsychotic medications available to treat schizophrenia—a devastating mental illness affecting approximately 1 percent of the population—were a double-edged sword. On the one hand, they helped control symptoms like hallucinations and paranoid thoughts. But they also had unpleasant side effects, like muscle stiffness, tremors, and abnormal movements that grew worse over time.

Thanks to new medicines introduced in the 1990s, people living with schizophrenia can now manage their condition more effectively than ever, and with fewer side effects. These medicines—dubbed “atypical antipsychotics” to distinguish them from earlier, “typical” drugs—also help people whose schizophrenia had not previously responded to treatment, making it possible for them to leave institutions.

Leukemia

If you had been diagnosed with chronic myeloid leukemia (CML) in 1999, chances were that you would not be alive today. Just 3 out of 10 patients survived for even five years. In the meantime, you had two daunting treatment options: a high-risk bone marrow transplant or daily injections of interferon, the side effects of which have been compared to “having a bad case of the flu every day of your life.”

You can take a daily pill that has a good chance of driving your cancer into remission—normalizing your blood count with few, if any, side effects. The new medicine targets CML on a molecular level, so it affects only the enzyme responsible for the disease. The tremendous effectiveness and precision of the approach is heralded as the “wave of the future.”
The Patient Perspective

- Life expectancy 26 months
- Treatment regime problematic

**HIV/AIDS**

Then: If you were diagnosed with AIDS in 1990, you might expect to live for only 26 months. During that time, you would be likely to contract a number of opportunistic infections that would make your remaining days unpleasant and painful. The only treatment available had to be taken every four hours—around the clock—and had serious side effects.

Now: Thanks to the approval in 1995 of protease inhibitors—and further advancements in new medicines and combination therapies in the decade since—the AIDS death rate in the United States has fallen by 70 percent. If diagnosed today, a range of treatment options (including different combinations of drugs) might be able to keep you symptom-free for years.

**Ulcers**

Then: Thirty-five years ago, treating an ulcer meant painful surgery that brought with it the risk of life-threatening infection and more ulcers in the future. Along with surgery, doctors often recommended weeks of bed rest, a mild fatty diet including boiled milk, and increased tobacco use, in an effort to stop the suspected culprits: a stressful lifestyle and spicy food. But none of these remedies made much difference to ulcer sufferers.

Now: In the late 1970s, new medicines were developed to heal the lining in the stomach or duodenum, making it possible for the first time to treat ulcers effectively without surgery. With the discovery that the bacterium H. pylori causes the vast majority of ulcers in 1982, doctors are now able to treat ulcers both quickly and permanently by targeting the real root of the problem—bacteria.

35 yrs ago surgery

Symptom free for a number of years – many treatment options

Treatable permanently without surgery
THE PATIENT PERSPECTIVE

Healthcare is a dynamic good:
Patients and society have reaped exceptional returns from medical innovation and have an enormous stake in its continued progress. Innovative medicines of the past are the commonly used generics of today.

Organ Transplant

Until early 60s rejection an issue

Transplants now common place

In the 1950s and early 1960s, patients needing an organ transplant were in a tragic bind. Transplants were surgically possible, but the body’s immune response rapidly rejected organs donated by unrelated individuals. People either died or led greatly diminished lives.

Thanks to anti-rejection medicines that were developed in the 1960s and 1980s, tens of thousands of Americans have received transplants of a wide variety of organs and are able to prolong their lives, regain their health, and maintain their independence.
R&D – VALUE TO AFRICA

• Multiple simultaneous epidemiological crises
• Parasitic diseases
• High levels of communicable diseases
• Chronic conditions escalating – Africa’s biggest health challenge by 2030 (Source: Economist Intelligence Unit 2012)
• Burden of “neglected” diseases
WHO IS FUNDING NEGLECTED DISEASE RESEARCH?

* Figures are adjusted for inflation and reported in 2007 US dollars

^ There may be minor under-reporting as some organisations did not submit 2009 data

13% pharma
WHERE IS RESEARCH FOCUSED?

Figure 5: Clinical activity by disease (with PDPs as lead sponsors, 2007-2012)

Pugatch MP et al. Assembling the pharmaceutical R&D puzzle for needs in the developing world
R&D INVESTMENT BY SECTOR

Pharma & biotech sector reinforces its position as top R&D investor worldwide
NEW PRODUCT DEVELOPMENT - A risky & expensive proposition

Years

Discovery (2–10 Years)

Phase I
20–80 Healthy Volunteers Used to Determine Safety and Dosage

Phase II
100–300 Patient Volunteers Used to Look for Efficacy and Side Effects

Phase III
1,000–5,000 Patient Volunteers Used to Monitor Adverse Reactions to Long-term Use

Preclinical Testing
Laboratory and Animal Testing

Regulatory Approval

Additional Post-marketing Testing

Up to 15 yrs to market

Compound Success Rates by Stage

5,000–10,000 Screened

250 Enter Preclinical Testing

5 Enter Clinical Testing

1 Approved by the FDA

1 to market

High Pharma R&D vs other sectors

Source: Tufts Center for the Study of Drug Development
PHARMA R&D IN SA

R1.75 billion – total industry R&D (2008)

R397 million – local subsidiaries

R1.35 billion – international HQs

Source: Deloitte Report, 2010. Insights into the high level contribution of the Pharmaceutical Industry in South Africa
EMBRACING INNOVATION – SA GOVERNMENT

An enabling IP framework in place predating TRIPS.
DTI
• Industrial Policy Action Plan – pharmaceuticals
• Various initiatives such as Ketlaphela project
DST boast:
• 10 year innovation plan, 2008
• Strengthening of the bio-economy
• SA urged to become a world leader in biotechnology and pharmaceuticals based on indigenous resources
• Investment in research - NHRC
ESSENTIAL MEDICINES

• Most African countries utilise an EML
• Industry study conducted in SA reflects that no medicines on SA EDL patent-protected
• Despite pro-generic environment, Governments still need recourse to innovative medicines that are safe, of good quality and efficacious
ADDRESSING NATIONAL HEALTH EMERGENCIES
ADDRESSING NATIONAL HEALTH EMERGENCIES

- Research & Development (R&D)
- Manufacturing Capacity
- Regulatory Mechanisms – safety, quality, efficacy
- Patents Registration Office
RESEARCH & DEVELOPMENT
MEDICINES INNOVATION BENEFITS PATIENTS

Direct benefits to patients through:

• Expanded number of treatments for complex diseases (HIV/AIDS, cancer etc);
• Improved treatments that more efficiently target diseases;
• Simplified medicine regimens that make patient’s lives easier
ASSA2008 projects a very much larger ARV programme. As a result, people live longer and hence the total living with AIDS increases substantially.

Figure 11: Increase in life expectancy due to new medicines
Cost of newer cardiovascular drugs compared to savings in hospitalization in 20 OECD countries (1995–2003)
<table>
<thead>
<tr>
<th></th>
<th>Actual hospitalizations avoided</th>
<th>Annual premature deaths avoided</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Actual prevention:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on current treatment rates</td>
<td>833,000</td>
<td>86,000</td>
</tr>
<tr>
<td><strong>Potential additional prevention:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If untreated patients received</td>
<td>420,000</td>
<td>89,000</td>
</tr>
<tr>
<td>recommended medicines</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Figure 12: Annual hospitalizations and deaths avoided through use of antihypersensitive medications*
MANUFACTURING CAPACITY
MANUFACTURING FOR AFRICA

• Currently we have only 129 plants in Africa  
  Source: African Development Bank 2011

• India and China dominate generic and API production

• Donor funding sources imports directly from India

• Security of supply?

• CIPIH encourages manufacturing in developing countries – Cuban example
REGULATORY MECHANISMS
REGULATORY STANDARDS MUST COMPLY WITH GLOBAL BEST PRACTICE

- Regulatory authorities
- GMP
- GLP
- GCP
- Pharmaceutical R&D
- Ethics and clinical practice
- Manufacturing
- Quality/laboratory
MEDICINES, A FUNDAMENTAL LINK IN THE HEALTHCARE CHAIN BUT, ONLY USEFUL IF...

- Quality guaranteed from manufacturer to patient (Quality)
- Available to patient when needed (Availability)
- Appropriate drug choice for patients need (Drug Selection)
- Dispensing: correct usage & patient compliance

ACCESS CHALLENGES ARE NOT IP RELATED
PATENTS OFFICE
MINIMUM REQUIREMENTS

- Respect for the standards of novelty, new inventive step and industrial applicability
- Patents to be granted within a reasonable period
CONCLUSION

• Many health challenges in Africa and developing world at large
• Challenges are not a constant - we need to keep abreast of their evolution
• Medicines will be needed to address these challenges
• Pharmaceuticals R&D is high investment with low success rate
• An enabling IP environment is critical to finding solutions to the health challenges of the present and future